Antiretroviral therapy coverage for PMTCT in Peru

Peru: Antiretroviral therapy coverage for PMTCT was 91.0% in 2024. ▲ Rising

Latest (2024)
91.0%
Change on year
up 3.4%
World rank
25th
of 84 countries
All-time high
96.0%
in 2022
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Antiretroviral therapy coverage for PMTCT in Peru, 2000–2024

0204060801002000201220242000: 0 % of pregnant women living with HIV2001: 0 % of pregnant women living with HIV2002: 22 % of pregnant women living with HIV2003: 42 % of pregnant women living with HIV2004: 27 % of pregnant women living with HIV2005: 14 % of pregnant women living with HIV2006: 36 % of pregnant women living with HIV2007: 55 % of pregnant women living with HIV2008: 51 % of pregnant women living with HIV2009: 56 % of pregnant women living with HIV2010: 40 % of pregnant women living with HIV2011: 59 % of pregnant women living with HIV2012: 68 % of pregnant women living with HIV2013: 68 % of pregnant women living with HIV2014: 69 % of pregnant women living with HIV2015: 65 % of pregnant women living with HIV2016: 69 % of pregnant women living with HIV2017: 70 % of pregnant women living with HIV2018: 81 % of pregnant women living with HIV2019: 90 % of pregnant women living with HIV2020: 93 % of pregnant women living with HIV2021: 90 % of pregnant women living with HIV2022: 96 % of pregnant women living with HIV2023: 88 % of pregnant women living with HIV2024: 91 % of pregnant women living with HIV

Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of pregnant women living with HIV.

Analysis

The most recent figure for antiretroviral therapy coverage for pmtct in Peru is 91.0%, measured in 2024.

That represents a change of up 3.4% on the previous year and up 31.9% over ten years.

Over the whole period, antiretroviral therapy coverage for pmtct in Peru peaked at 96.0% in 2022 and was at its lowest, 0.0%, in 2000.

That places Peru 25th out of 84 countries with data for 2024, putting it in the middle of the range.

The long-run direction has been consistently rising across the 25 years of available data.

Antiretroviral therapy coverage for PMTCT in Peru, year by year

Annual values for Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV) in Peru, 2000 to 2024.
Year % of pregnant women living with HIV Change
2000 0.0%
2001 0.0%
2002 22.0%
2003 42.0% +90.9%
2004 27.0% -35.7%
2005 14.0% -48.1%
2006 36.0% +157.1%
2007 55.0% +52.8%
2008 51.0% -7.3%
2009 56.0% +9.8%
2010 40.0% -28.6%
2011 59.0% +47.5%
2012 68.0% +15.3%
2013 68.0% +0.0%
2014 69.0% +1.5%
2015 65.0% -5.8%
2016 69.0% +6.2%
2017 70.0% +1.4%
2018 81.0% +15.7%
2019 90.0% +11.1%
2020 93.0% +3.3%
2021 90.0% -3.2%
2022 96.0% +6.7%
2023 88.0% -8.3%
2024 91.0% +3.4%

Peru compared with similar countries

  • Peru's 91.0% is above the median for upper middle income countries, which is 79.5%, 1.1× the median. (22 countries reporting)
  • Peru's 91.0% is above the median for Latin America & Caribbean, which is 68.0%, 1.3× the median. (15 countries reporting)

Biggest year-on-year movements

Years where Antiretroviral therapy coverage for PMTCT in Peru changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.

YearChange FromTo
2006 +157.1% 14.0% 36.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 30.3% 0.0% 56.0% 10
2010s 67.9% 40.0% 90.0% 10
2020s 91.6% 88.0% 96.0% 5

Countries ranked near Peru

  1. 22 Canada 92.0% compare
  2. 22 Ethiopia 92.0% compare
  3. 22 Tajikistan 92.0% compare
  4. 26 Armenia 90.0% compare
  5. 26 Benin 90.0% compare
  6. 26 Kenya 90.0% compare
  7. 26 Kyrgyzstan 90.0% compare

See the full ranking of 99 places →

More health data for Peru

All data for Peru →

Frequently asked questions

What is antiretroviral therapy coverage for pmtct in Peru?
Antiretroviral therapy coverage for pmtct in Peru was 91.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
What is the highest antiretroviral therapy coverage for pmtct recorded in Peru?
The highest recorded value was 96.0% in 2022.
What is the lowest antiretroviral therapy coverage for pmtct recorded in Peru?
The lowest recorded value was 0.0% in 2000.
How does Peru rank for antiretroviral therapy coverage for pmtct?
Peru ranks 25th out of 84 countries with data for 2024.
Is antiretroviral therapy coverage for pmtct rising or falling in Peru?
Over the last ten years it is up 31.9%. The long-run trend across the full record is rising.
Where does this Peru data come from?
The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Antiretroviral therapy coverage for PMTCT in Peru. Statizoid, drawing on UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Retrieved 17 September 2026, from https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/peru/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/peru/">Antiretroviral therapy coverage for PMTCT in Peru</a> — Statizoid

About this data

Indicator
Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV)
Unit
% of pregnant women living with HIV
Source
UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS)
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
99 places, 2,393 data points, 2000–2024
Last refreshed

Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).